Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrombopag for chemotherapy-induced thrombocytopenia
CTR20192643Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of hetrombopag in chemotherapy-induced thrombocytopenia (CIT), sponsored by Hengrui Therapeutics. Started Jan 2020; status: completed.
02
Drugs
hetrombopag
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on CTR20192643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192643.